On September 3, 2020 Bio-Techne Corporation (NASDAQ:TECH) reported that Chuck Kummeth, President and Chief Executive Officer, will present at the 2020 Wells Fargo Virtual Healthcare Conference on Wednesday, September 9, 2020 at 11:20 a.m. EDT (Press release, Bio-Techne, SEP 3, 2020, View Sourcepress-releases/detail/207/bio-techne-to-present-at-the-2020-wells-fargo-virtual" target="_blank" title="View Sourcepress-releases/detail/207/bio-techne-to-present-at-the-2020-wells-fargo-virtual" rel="nofollow">View Source [SID1234564415]). A live webcast of the presentation can be accessed via Bio-Techne’s Investor Relations website at View Source or through the following link (webcast).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 3, 2020 TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, reported that George Yeh, President of TLC, will be presenting the latest updates on the company in a fireside chat with Madhu Kumar, Senior Research Analyst, at Baird’s 2020 Global Healthcare Conference on Wednesday, September 9, 2020 at 8:30am ET (Press release, Taiwan Liposome Company, SEP 3, 2020, View Source [SID1234564414]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 30-minute fireside chat will include a company overview followed by a Q&A session. During the conference, which is taking place virtually September 9-10, 2020, TLC will also be participating in one-on-one sessions. While the fireside chat is only accessible to Baird clients registered for the event, a corporate presentation entailing the updates will be available on the company’s website at www.tlcbio.com under the Investors section.

On September 2, 2020,Idera Pharmaceuticals reported that the Company and Lincoln Park entered into a First Amendment to Purchase Agreement (the "Amended Purchase Agreement") (Filing, 8-K, Idera Pharmaceuticals, SEP 2, 2020, View Source [SID1234564413]). The primary purpose of the Amended Purchase Agreement was to reference the Company’s Registration Statement on Form S-3, Registration No. 333-240366 (the "Registration Statement"), rather than the registration statement that had been referenced at the time of the Purchase Agreement, and facilitate a corresponding increase in the number of shares of Common Stock issuable under the Exchange Cap (as defined in the Amended Purchase Agreement). The Amended Purchase Agreement limits the Company’s sale of shares of Common Stock to Lincoln Park from the date thereof to 7,036,329 shares of Common Stock, representing 19.99% of the shares of the Common Stock outstanding on the date of the Amended Purchase Agreement unless (i) shareholder approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock to Lincoln Park under the Amended Purchase Agreement equals or exceeds $2.05 per share, which represents the lower of (A) the closing price of the Common Stock on the Nasdaq Capital Market immediately preceding the date of the Amended Purchase Agreement or (B) the average of the closing prices of the Common Stock on the Nasdaq Capital Market for the five Business Days immediately preceding the date of the Amended Purchase Agreement, as calculated in accordance with Nasdaq Rules.

On September 3, 2020 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, reported that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the following upcoming investor conferences (Press release, Ultragenyx Pharmaceutical, SEP 3, 2020, View Source [SID1234564412]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 15th Annual BioPharma Virtual Conference as part of a panel discussion on Wednesday, September 9, 2020 at 4:15 PM ET.

Morgan Stanley Virtual 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020 at 12:30 PM ET.

BofA Securities Virtual Global Healthcare Conference on Wednesday, September 16, 2020 at 11:45 AM ET.
The live and archived webcast of the presentation will be accessible from the company’s website at View Source The replay of the webcast will be available for 90 days.

On September 3, 2020 Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), reported that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the Wells Fargo Virtual Healthcare Conference on Wednesday, September 9, 2020 at 10:40 AM EDT (Press release, Regulus, SEP 3, 2020, View Source [SID1234564410]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available through the investor relations section of the Company’s website at www.regulusrx.com.